Publications by authors named "N C Homann"
Background: Although addition of adjuvant chemotherapy is the current standard, the prognosis of pancreatic cancers still remains poor. The NEPAFOX trial evaluated perioperative treatment with FOLFIRINOX in resectable pancreatic cancer.
Patients And Methods: This multicenter phase II trial randomized patients with resectable or borderline resectable pancreatic cancer without metastases into arm (A,) upfront surgery plus adjuvant gemcitabine, or arm (B,) perioperative FOLFIRINOX.
Purpose: This trial evaluates the addition of the PD-L1 antibody atezolizumab (ATZ) to standard-of-care fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) as a perioperative treatment for patients with resectable esophagogastric adenocarcinoma (EGA).
Methods: DANTE started as multicenter, randomized phase II trial, which was subsequently converted to a phase III trial. Here, we present the results of the phase II proportion, focusing on surgical pathology and safety outcomes on an exploratory basis.
Article Synopsis
- Esophagogastric adenocarcinoma (EGA) is a growing global health concern, with current treatment for localized cases involving a triplet chemotherapy regimen (FLOT) followed by surgery, while HER2-targeted therapies and PD-1 inhibitors have shown promise in metastatic cases.
- The PHERFLOT study is a phase II clinical trial evaluating the effectiveness and safety of combining pembrolizumab, FLOT, and trastuzumab in treating localized HER2-positive EGA, involving 30 patients and focusing on key endpoints like complete response rate and disease-free survival.
- Preliminary findings suggest that adding trastuzumab to perioperative therapy improves outcomes, and ongoing research is exploring how immune responses and other biomarkers can further
Introduction: Postprocedural bleeding is a major adverse event after endoscopic resection of colorectal lesions, but the optimal surveillance time after endoscopy is unclear. In this study, we determined onset time and characteristics of postprocedural bleeding events.
Methods: We retrospectively screened patients who underwent endoscopic resection of colorectal lesions at three German hospitals between 2010 and 2019 for postprocedural bleeding events using billing codes.
This multicenter, randomized phase II/III study evaluated the addition of the vascular endothelial growth factor receptor-2 inhibitor ramucirumab to FLOT as perioperative treatment for resectable esophagogastric adenocarcinoma. Patients received either FLOT alone (Arm A) or combined with ramucirumab followed by ramucirumab monotherapy (Arm B). The primary endpoint for the phase II portion was the pathological complete or subtotal response (pCR/pSR) rate.
View Article and Find Full Text PDF